Cantor Fitzgerald Reiterates Overweight on PTC Therapeutics, Maintains $51 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on PTC Therapeutics (NASDAQ:PTCT) and maintained a price target of $51.
November 20, 2023 | 2:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst Kristen Kluska reaffirmed an Overweight rating on PTC Therapeutics with a steady price target of $51.
The reiteration of an Overweight rating and the maintenance of a price target by a reputable analyst like Kristen Kluska can be seen as a positive endorsement of PTC Therapeutics' stock, potentially influencing investor sentiment and the stock's short-term performance positively.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100